Please login to the form below

Not currently logged in
Email:
Password:

Newron Pharma

This page shows the latest Newron Pharma news and features for those working in and with pharma, biotech and healthcare.

Newron back on track for Xadago approval in US

Newron back on track for Xadago approval in US

Newron Pharma will not have to conduct any additional clinical trials for its Parkinson's disease drug Xadago in the US, setting up a new FDA filing in the coming weeks. ... Now, Newron is planning to refile a marketing application with the FDA in

Latest news

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    In 2015, a total of 44 New Molecular Entities (NMEs) were approved for marketing in countries around the world, maintaining the high output from pharma industry pipelines of the last few ... neprilysin inhibitor. Novartis. USA. safinamide. Xadago.

  • Chasing the cure for Parkinson's disease Chasing the cure for Parkinson's disease

    Generic versions of this drug combination are also available, including Parcopa (Azur Pharma). ... Currently available therapies of this class include selegiline and rasagiline. Safinamide (Newron, Zambon and Meiji Seika Pharma) is a selective and

More from news
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Newron Pharma appoints commercial affairs VP Newron Pharma appoints commercial affairs VP

    Newron Pharma appoints commercial affairs VP. Dennis Dionne brings expertise from J&J and Novartis. ... Milan, Italy-based Newron Pharmaceuticals has promoted Dennis Dionne to vice president of commercial affairs.

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics